U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. ClinicalTrials.gov – a Three-Part Series
  1. News & Events for Human Drugs

ClinicalTrials.gov – a Three-Part Series

DATE

On Demand

Visit CDER Small Business and Industry Assistance Page

ABOUT THIS EVENT

In a three-part webinar series, FDA provides a general overview of ClinicalTrials.gov and relevant definitions, laws, and regulations for complying with ClinicalTrials.gov registration and results information submission requirements. Participants will gain an understanding of CDER’s role and responsibilities with respect to ClinicalTrials.gov oversight and will hear examples of compliance and enforcement activities CDER has taken to encourage compliance.

INTENDED AUDIENCE

  • Sponsors, sponsor-investigators and clinical investigators designated as responsible for submitting registration and results information to ClinicalTrials.gov

TOPICS COVERED

  • FDA’s roles and responsibilities with respect to ClinicalTrials.gov oversight
  • An overview of ClinicalTrials.gov definitions, laws, and regulations
  • An overview of CDER’s compliance and enforcement activities with respect to ClinicalTrials.gov requirements, including case examples

FDA RESOURCES

Topics & Presentations

Speakers

ClinicalTrials.gov: Part 1

 

Meeting Transparency and Reporting Requirements

Miah Jung, Pharm.D.
Supervisory Pharmacologist
Division of Enforcement and Postmarketing Safety (DEPS) | Office of Scientific Investigations (OSI) | Office of Compliance (OC) | Center for Drug Evaluation and Research (CDER) | FDA

ClinicalTrials.gov: Part 2

 

Definitions, Laws, and Regulations

Jan Hewett, J.D.
Regulatory Counsel
Policy Office (PO) | OSI | OC | CDER | FDA

ClinicalTrials.gov: Part 3

 

CDER’s Compliance and Enforcement Activities

Rachelle Swann, Pharm.D.
Lead Pharmacologist
DEPS | OSI | OC | CDER | FDA

 

Back to Top